Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy

Nina Eissler
,
Renske Altena
,
Ali Alhuseinalkhudhur
,
Olga Bragina
,
Joachim Feldwisch
,
Guido Wuerth
,
Annika Loftenius
,
Nikolai Brun
,
Rimma Axelsson
ORCID logo ,
Vladimir Tolmachev
ORCID logo ,
Jens Sörensen
ORCID logo ,
Fredrik Y Frejd
* ORCID logo
Version 1 : Received: 18 April 2024 / Approved: 18 April 2024 / Online: 19 April 2024 (15:08:53 CEST)

How to cite: Eissler, N.; Altena, R.; Alhuseinalkhudhur, A.; Bragina, O.; Feldwisch, J.; Wuerth, G.; Loftenius, A.; Brun, N.; Axelsson, R.; Tolmachev, V.; Sörensen, J.; Frejd, F.Y. Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy. Preprints 2024, 2024041295. https://doi.org/10.20944/preprints202404.1295.v1 Eissler, N.; Altena, R.; Alhuseinalkhudhur, A.; Bragina, O.; Feldwisch, J.; Wuerth, G.; Loftenius, A.; Brun, N.; Axelsson, R.; Tolmachev, V.; Sörensen, J.; Frejd, F.Y. Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy. Preprints 2024, 2024041295. https://doi.org/10.20944/preprints202404.1295.v1

Abstract

Human epidermal growth factor receptor 2 (HER2) is a major prognostic and predictive marker overexpressed in 15- 20 % of breast cancers. The diagnostic reference standard for selecting patients for HER2-targeted therapy is by analysis of tumor biopsies for HER2 expression and amplification. Previously patients were either defined as HER2-positive or negative, however, with approval of novel treatment options, specifically the antibody-drug conjugate trastuzumab deruxtecan, many breast cancer patients with tumors expressing low levels of HER2 and lacking HER2 amplification have become eligible for HER2-targeted therapy. Such patients will need to be reliably identified by suitable diagnostic methods. Biopsy-based diagnostics are invasive, and repeat biopsies are not always feasible. They cannot visualize heterogeneity of HER2 expression, leading to a substantial number of misdiagnosed patients. An alternative and highly accurate diagnostic method is mo-lecular imaging with radiotracers. In case of HER2, various studies demonstrate the clinical utility and feasibility of such approaches. Affibody-based radiotracers are clinically validated molecules with favorable characteristics for imaging. In this article we summarize the HER2-targeted therapeutic landscape, describe the experience with imaging diagnostics for HER2, and review the currently available clinical data on HER2-Affibody-based molecular imaging as novel diagnostic tool in breast cancer and beyond.

Keywords

HER2; breast cancer; diagnostics; molecular imaging; Affibody molecules; clinical trials

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.